Noninvasive biological response medical device maker NanoVibronix (NAOV) jumped more than 30% in premarket trading Monday.
The company announced a positive report concerning its device for urinary tract infections and was also featured in an article the Journal of Medical & Surgical Urology due to overwhelmingly positive results from a study of patients that used its UroShield device in real world settings.
More than 20 patients with reoccurring UTIs used UroShield for a minimum period of 12 weeks. Researchers at Coventry University concluded that Uroshield reduced the number of UTIs, catheter blockages and changes, and the need for antibiotics.
The company said that researchers at Covetry University concluded that UroShield reduced the number of UTIs, catheter blockages and changes, and consequently, the need for antibiotics.